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Abstract
Problem: There is gap in time from when a Tepezza (teprotumumab) order is placed until a
patient receives their first infusion.
Context: Delays in the initiation of Tepezza therapy result in worsening symptoms and a
decrease in quality of life for patients diagnosed with thyroid eye disease.
Interventions: Interventions included scheduling regular meetings with involved departments,
following each patient who has been prescribed Tepezza through the initiation of therapy, and
improving staff and patient education.
Measures: Outcome measures include decreasing days from order placement to first infusion
from an average of 61 days to 30 days or less and increasing patient education and satisfaction.
Process measures consist of establishing regular meetings with stakeholders, following patients
from order to first infusion to collect data, creating a patient education pamphlet, and initiating a
patient satisfaction survey. Balancing measures include maintaining regular meetings with
stakeholders to assure that other involved departments do not sustain additional burden with new
clinic workflows.
Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30
days from the time the order was initiated.
Conclusions: A timely benefits investigation, in addition to improved communication amongst
stakeholders, led to the improvement in the previous delays in care.
Keywords: Thyroid eye disease, TED, Tepezza, teprotumumab, Graves’ disease, optic
nerve compression, insurance authorization, prior authorization, treatment delays,
benefits investigation
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Tepezza: Improving Delays in Treatment
Section II: Introduction
Lack of timely insurance authorizations is a significant problem in our health care
system. This is especially true for costly, intravenous medications. These ordered treatments are
often time sensitive and required for patient safety and quality of life. However, delays in patient
care seem to be at an all-time high for many prescribed therapies. In a poll conducted by the
Medical Group Management Association (MGMA) in May 2021, 81% of medical personnel
reported an 81% increase in prior authorization requirements in the last year (Ernst, 2021).
Likewise, communication failures and a lack in coordination of care also, and maybe
equally, contribute to the failure of patients receiving their prescribed treatments in a timely
manner. In fact, poor communication among healthcare workers and teams is one of the leading
causes in patient harm and poor outcomes (HIPAA Journal, 2022). The Institute of Medicine
(IOM) recognizes that care coordination is a crucial component in improving the safety and
effectiveness of our healthcare system (Agency for Healthcare Research and Quality [AHRQ],
2018).
This paper will focus on current treatment delays of one medication, Tepezza
(teprotumumab). Tepezza is a medication prescribed to treat moderate to severe thyroid eye
disease (TED). In the microsystem of an ambulatory endocrinology clinic, there is a gap in care
from when Tepezza is ordered and when patients are scheduled for their initial infusions.
Sometimes, this gap in time proves detrimental to patients’ health. This quality improvement
(QI) project was chosen after interviewing physicians and staff members from the clinic. This
team verbalized safety concerns for their patients who are prescribed Tepezza. Specifically, the
concern is that Tepezza is not started in a timely manner.
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The clinic team believes there is an opportunity for improvement with the current
Tepezza program. Identifying the cause or causes of the current delays in addition to initiating
improvements with the current workflows will impact patient safety and outcomes, as well as
overall patient satisfaction. In addition, making the needed improvements will impact the
organization by improving communication between the involved departments and by reducing
potential duplicate work and unnecessary tasks identified in the current workflow. This project is
in line with many organizational priorities, but especially that of patient centered care (PCC).
Healthcare organizations globally have shifted their focus to one of PCC, which includes caring
for the whole person, rather than focusing on the disease process only (Bokhour, et al., 2018).
Problem Description
Thyroid eye disease is the most common autoimmune disease affecting the eye (MunozOrtiz et al., 2020). It is diagnosed most often in patients who have Graves’ disease. Thyroid eye
disease is progressive, with the active phase lasting from six to 24 months (NORD, 2021). It is
usually diagnosed when the optic nerve is compressed, leading to various changes in vision
including loss of color vision, loss of sharpness of vision, and dimmed vision. Other reported
symptoms of TED include blurred vision, diplopia, eye pain, photophobia, tearing of the eye,
restricted eye movement, retraction of the eyelids, and exophthalmos. In severe cases of TED,
patients could develop corneal ulcers and permanent loss of vision (Cleveland Clinic, 2021).
Tepezza is prescribed to reduce the inflammation caused by TED. An unnecessary delay
in scheduling this infusion could result in a decrease in quality of life, worsening symptoms, and
even blindness. Once each month, an endocrinologist and an ophthalmologist hold a joint TED
clinic to assess their mutual patients who have a diagnosis of thyroid eye disease. During a visit
to the TED clinic, a patient may be prescribed a course of eight Tepezza infusions, which are
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given intravenously every three weeks. Depending on insurance approval, a patient may receive
Tepezza at an infusion center or at home. Patients seek treatment in this endocrinology clinic to
improve symptoms and preserve their vision. As with any new medication, approved
authorizations were difficult to obtain in the first many months following the U.S. Food and
Drug Administration (FDA) approval of Tepezza on January 21, 2020 (FDA, 2020). However,
this clinical microsystem continued to see delays in scheduling Tepezza infusions. A root cause
analysis was done with staff participation in this quality improvement (QI) project (see Appendix
A).
The current process is not working. Neither the endocrinology clinic nor the prescribing
providers are being informed when patients are scheduled for infusion therapy or if they are
unable to be scheduled due to denial of authorization. The two causes identified as most
problematic by the team include the untimely authorization approval and the lack of
communication between involved stakeholders. For this QI project, metrics that matter include
the current number of days from the order placement to the first infusion as well as the desired
outcome of providing the first Tepezza infusion within 30 days of the order placement. The
current quality gap lies in the lack of communication between departments regarding insurance
authorization, as well as a lack of educating patients about potential PA requirements and the
expected time frame from order to infusion.
The American Medical Association (AMA) surveyed 1,000 physicians about the impact
prior authorizations (PAs) have on patients and providers. Of those surveyed, 93% reported that
PAs cause delays in patient care, and 34% state that PAs have caused significant adverse events
for their patients. Currently, the AMA is working to change PA requirements and policies
(AMA, 2022). But for now, the delays in care remain. Most infused medications require prior
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authorization. In one study, which measured the length in time from order placement to
medication infusion, 71% of orders placed required a PA. Of these, 21% of the initial PAs were
denied and required an appeal. This process delayed infusions by an average of 50 days
(Wallace, et al., 2019).
At the beginning of the project, 36 TED patients were identified as either awaiting PA
status, having already started Tepezza therapy, or being lost to follow up. Of these patients,
twelve were awaiting PA approval, fourteen were in process of treatment, and ten were lost to
follow up (see Appendix B). Patients whose treatments were pending authorizations had already
waited an average of 61 days since the orders were placed. By taking a systems approach to the
current challenges presented, the interdisciplinary team has an opportunity to improve patient
safety and outcomes.
Available Knowledge
In patients treated with Tepezza, how do weekly stakeholder meetings compared to no
meetings decrease drug authorization wait times over six months? An electronic literature search
was performed using the following databases to research Tepezza, thyroid eye disease, prior
authorization requirements, and a lack of effective communication; CINAHL, Cochrane Library,
and PubMed. Research was also done using the following websites; The Cleveland Clinic,
National Organization of Rare Disorders, and U.S. Food and Drug Administration, American
Medical Association, American Nurses Association, and Agency for Healthcare Research and
Quality. The search included the years 2018 until present. Keywords included in the search were
thyroid eye disease, TED, Tepezza, teprotumumab, Graves’ disease, optic nerve compression,
insurance authorization, prior authorization, treatment delays, benefits investigation, improved
communication, and lack of communication in teams.
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Thirteen supporting articles were initially identified. Of those, five scholarly articles were
rated using the Johns Hopkins Nursing Evidence Based Practice (JHNEBP) Appraisal Rating
Toolkit (Dang & Dearholt, 2019). The selected articles were rated at evidence levels I, II, and III
and were classified as good or high quality (see Appendix C). Four of these articles strengthen
the QI project by providing supporting evidence related to the improvement of TED symptoms
following timely treatment with Tepezza. One article provides supporting evidence regarding
delays in care due to current prior authorization requirements.
Chin et al., (2020), published a quasi-experimental, retrospective study that included
26,804 patients from fifty-seven articles. The purpose of the study was to assess the global
prevalence of TED in patients with a known diagnosis of Graves’ disease. The results showed
that TED presented in 40% of patients who had a previous diagnosis of Grave’s disease
worldwide. The results per specific continent or region include; 38% in Europe, 44% in Asia,
27% in North America, 58% in Oceania, 35% in Southeast Asia, and 48% in the Middle East. In
addition to geographical areas considered, prevalence of symptoms was described. Lid retraction
and proptosis occurred in 57%, diplopia in 36%, and ocular hypertension occurred in 13%.
Further, 10% of TED patients presented with neither abnormal thyroid function labs nor a
clinical presentation of hyperthyroid symptoms.
Smith et al., produced a double-masked, placebo study including a total of 88 TED
patients with moderate to severe ophthalmopathy symptoms between the ages of 17 and 75 years
old. Participants received an IV infusion of either Tepezza or a placebo every three weeks for 24
weeks. Seventy-six patients completed the study, which concluded that Tepezza is not only more
effective, but it also produces a therapeutic effect sooner, than that of a placebo. The study
included three phases: screening, intervention, and follow-up. During screening, patients were
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assessed for proptosis by examination and quality of life by questionnaire. Patients were
reassessed for proptosis and quality of life at regular intervals during the intervention phase. At
week six of phase two, researchers noted a remarkable reduction of proptosis in patients
receiving Tepezza compared to those who received a placebo. Improvement in quality of life was
also significantly increased in patients who received Tepezza versus the patients who received
placebo.
In a retrospective cohort study by Wallace, et al., (2020), researchers reviewed records of
225 patients who were prescribed intravenous infusions. Of these, 71% required a prior
authorization (PA). Of the prior authorizations submitted, 21% were initially denied by payers
and required additional actions such as appeals and peer-to-peer discussions to obtain approval to
proceed with the prescribed therapy. Appeals were successful in 79% of these. This study was
conducted between July 2016 and June 2018. Data was collected from one location only using
the electronic medical record (EMR) system. PA denials caused delays in patient care.
Considering that the great majority of required PAs are approved, researchers note that the
current requirements should be reconsidered.
In a randomized control trial, Douglas (2019) studied Tepezza prior to its approval for
use by the U.S. Food and Drug Administration (FDA). At the time, there was no approved
pharmalogical treatment of TED. The only therapies used up to that point were ordered for
symptom management. Optic nerve decompression surgery was the only treatment option, and
this was reserved for extreme cases. Douglas studied Tepezza as a potential alternative to
surgery. The study included adult patients between the ages of 18 and 75 years old in active TED
and without prior treatment. They were given either Tepezza or a placebo every three weeks for
24 weeks. The patients were assessed for improved proptosis throughout the study. At week 24,
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55% of patients treated with Tepezza were noted to have a high response, which is defined as a
reduction in proptosis by at least three millimeters from their baseline assessment, compared to
10% of patients treated with the placebo. Tepezza could offer an alternative to optic nerve
decompression surgery.
Munoz-Ortiz, et al., (2020), conducted a retrospective and cross-sectional study which
assessed the prevalence of TED in not only patients with hyperthyroid, but also in hypothyroid
and euthyroid patients. The researchers included a review of thirteen articles from four
continents that were published between the years of 1996 and 2018. The prevalence of
hyperthyroid in TED patients was 86%. A diagnosis of primary hypothyroidism occurred in 10%
of TED patients. It was also noted that 8% of TED patients presented in a state of euthyroid. The
researchers encourage providers to further assess patients who present with symptoms of TED
despite thyroid function tests that do not support hyperthyroidism.
The articles described support the QI project, as they highlight the importance of the
timely treatment of TED. Delays in treatment contribute to patient harm. Prior authorization is a
time-consuming process. Breakdown of communication leads to further delays and contributes to
worsening symptoms and sometimes costlier health care needs of TED patients. The information
presented was strong and can be utilized to further demonstrate the need for improved
communication between team members and improved delays in the delivery of care.
Rationale
The framework used for this project is the Lean Six Sigma (LSS) methodology of define,
measure, analyze, improve, and control (DMAIC) (Monday, 2022). LSS combines two
methodologies. The first is Lean, which is aimed at reducing waste, while the goal of the second,
Six Sigma, is to limit variation. Lean Six Sigma was chosen because it provides a data-driven
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structure for problem-solving existing issues and identifying other opportunities for improvement
(Monday, 2022). LSS guided this project by helping the QI team to identify root causes that were
leading to the delay in care and then by steering the team to make necessary workflow changes
to assure that the goal of scheduling the initial Tepezza infusion within 30 days is sustained.
Project Aim
The primary goal of the team weas to decrease the time from the placement of a new
Tepezza order to when a patient is scheduled for their first infusion to 30 days or less. They
planned to achieve this goal by increasing communication among stakeholders and patients. The
goal is measurable by data collection utilizing chart review and case conferences with involved
departments to track the number of days from order placement to initial infusion. Secondary
goals included improving patient education and satisfaction scores and to improve staff training.
The project is relevant to this microsystem as it aims to improve patient safety and outcomes (see
Appendix D).
Section III: Methods
Context
Purpose
The purpose of the quality improvement project is to improve the delay in treatment,
which could cause further loss of vision and even total loss of vision for TED patients.
Improving the gap in time will decrease the chances of patient harm. Delays in treatment have a
significant financial impact on patients as well as on healthcare organizations. In 2017, the
average cost for hospitalizations related to thyroid eye disease was $59,103, and emergency
department visits for patients with TED cost an average of $6,018. The total cost for treating
patients with TED in 2017 surpassed $135.5 million (Singh et al., 2021).

11
Clinic costs associated with this QI project are minimal and include the direct costs of
staffing hours for training and sustaining workflows and the indirect costs of printing educational
materials for patients (see Appendix E). One RN and one MA participate in one hourly meeting
per week with the ordering physicians and a pharmaceutical representative. In addition, the same
RN and MA participate in bi-weekly meetings with additional stakeholders. Combined, these
meetings are projected to incur labor costs of $9,200.00 annually. There are no start-up costs
associated with this project. This QI project will generate a return on investment (ROI) for the
organization by decreasing patient and organizational costs as a result for preventing
unproductive clinic visits and hospitalizations. There is an average of four new Tepezza orders
placed each month. For these approximately 36 patients per year, the clinic will now provide a
patient educational pamphlet as well as a patient satisfaction survey. These printed materials
incur a cost of less than $100.00 annually. Additional funds for labor were included in the
requests for the FY 2022 budget. The printed materials are minimal and were not included in the
annual budget requests. The ROI was calculated by considering the cost savings of preventing
unproductive office visits related to the increased cost of labor needed to sustain this project.
This project is considered a break even analysis (see Appendix E).
Patients
The microsystem assessed is a busy specialty care clinic treating patients with
uncontrolled endocrinology diagnoses. One subspecialty of this clinic is providing care for
patients diagnosed with thyroid eye disease . The endocrinology clinic treats adult patients who
are 18 years and older. Thyroid eye disease is usually diagnosed in middle aged women. It is
most associated with Graves’ disease, an autoimmune disorder causing an overactive thyroid
gland (NORD, 2020). Rarely, TED occurs in patients with hypothyroidism or euthyroidism
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(Munoz-Ortiz et al., 2020). When the optic nerve is compressed, various changes in vision occur.
TED patients seek care in this clinic for symptom relief and eyesight preservation. Of the initial
36 patients identified at the beginning of the QI project, 31 were women and five were men. The
youngest patient was 34 years old, and the oldest patient was 72 years old.
Professionals
The clinic faculty consists of sixteen physicians, and the clinic staff consists of three
advanced practice providers, five registered nurses, two dietitians, and fourteen medical
assistants. The providers see patients in two main locations and four satellite locations.
Combined, this specialty clinic serves an average of 100 patients per day. A microsystem
assessment was performed, and a QI team was identified (see Appendix F). Within the clinic,
medical assistants (MAs) focus on clerical duties, such as scheduling and pending lab orders and
refill requests. Registered Nurses (RNs) assist with clinical concerns and needs, such as triaging
symptomatic patients, providing advice, and helping to answer other medical questions. They
also assist with placing orders per clinic protocols and relaying information from providers to
patients. The Advanced Practice Provider (APP) team sees patients in clinic between visits with
attending physicians. They work closely with the attending providers to manage patients and
update care plans appropriately. Appointment frequency for unstable patients is at least every
three months and for stable patients every six to twelve months. The clinic receives internal and
external referrals. And when identified, they may receive referrals from other clinicians within
the clinic for patients who need subspecialty care. Hyperthyroidism is the fifth most prevalent
diagnosis seen in the clinic.
The QI team members include a medical assistant, a registered nurse, a nurse practitioner,
the clinic manager, and two physicians, including an endocrinologist and an ophthalmologist.
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The physicians make a treatment plan for TED patients seen in their clinics. If Tepezza is
ordered, a therapy plan is entered into the medical records. Follow up appointments may be with
one physician, both physicians, or the nurse practitioner. The MA staff member assists with
scheduling TED patients as well as following the PA status for patients in process of Tepezza
initiation. They also attend the once monthly joint TED clinic scheduled for patients who see
both the endocrinologist and the ophthalmologist in the same day. The RN triages medical
questions and symptom calls and escalates to providers as needed. Clinic leadership facilitates
meetings and updates the improvement project status on the visibility wall, which is a
communication point within the clinic that includes information that should be shared with clinic
staff. Other involved stakeholders include members of the patient financial clearance (PFC)
team, the internal infusion center team, the central pharmacy, and the pharmaceutical
representatives.
In addition, the IHI Clinical Microsystem Assessment Tool was completed (see Appendix
G). Within the endocrinology clinic, leaders are engaged with and supportive of staff. Leaders
build rapport with each team member and utilize tools to help identify and further develop
individual strengths. There is an opportunity for leaders to improve clinic specific competencies
and to improve the onboarding process for new staff. There is also an opportunity to improve
potential burnout by reevaluating the current workload and assignments for each team member.
This clinic uses a care team model for patient care. The interdisciplinary team for each patient
includes the physician, an APP, an RN, and an MA. Patient education is provided when care is
established outlining the responsibilities of each team member and highlighting their partnership
in each patient’s ongoing care. An opportunity for improvement is responding to patient
messages and requests in a timelier manner. There are no outreach programs associated with this
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microsystem. However, staff refers to social work when needed. Organizational goals as well as
clinic improvement projects are updated regularly and discussed in team huddles. The
Information Technology (IT) department is engaged with patient experience. IT support is also
available to staff during all operating hours.
A SWOT analysis was performed with the clinic QI team (see Appendix H). One
identified strength is that the team as well as the physician partners are engaged and invested in
the success of this project. Another strength is that there is an existing relationship between the
clinic and the pharmaceutical representatives. A third strength is that this project incurs a low
cost to implement and maintain. Weaknesses include a lack of established relationships with
other stakeholders, as well as a lack of patient education and staff knowledge about the Tepezza
program. The team welcomed the opportunity to establish relationships with others involved in
the Tepezza program by initiating regular meetings. Other opportunities include improving
patient education and staff training. The success of this project will also make an impact on cost
savings to the patients and the organization by reducing and preventing hospitalization. Threats
to accomplishing the team goals include lengthy PA authorization processes for some payors, PA
denials, which often require appeals or peer-to-peer discussions, potential staff turnover, which
without successful onboarding of new staff could lead to holes in staff knowledge, and patients
who refuse treatment or are lost to follow up.
Processes
The process at the beginning of the project was inefficient. Once a Tepezza order was
placed, it went to the Patient Financial Clearance (PFC) work queue for insurance authorization.
If approved, a patient would be scheduled in the internal infusion center. If denied, the order was
sent to the internal home infusion authorization team. At that time, a second PA was completed.
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If approved, a patient would be scheduled for Tepezza infusion utilizing the internal home
infusion team. However, if this PA was also denied, a referral was placed to the pharmaceutical
representatives, who then performed a benefits investigation to learn the insurance plans
preferred infusion site, if any. If approved, a patient would be scheduled at the approved
location. If denied, the ordering provider should be informed. The provider may decide to
request an appeal or a peer-to-peer discussion, or they may choose an alternative therapy. Neither
the endocrine clinic nor the prescribing providers were being routinely informed when patients
were scheduled for infusion therapy or if they were unable to be scheduled due to the denial of
insurance authorization. Most commonly, the providers were seeing patients in the clinic for
follow-up visits and finding out then that therapy had not yet been initiated. Occasionally, the
providers learn that their patients have not received their treatment due to hospital admissions.
Patterns
The current patterns include initiating multiple PAs for most patients. The first PA is
done as an attempt to schedule the prescribed infusions at the internal infusion center. While the
organization has a vested interest in keeping the business, the physicians have historically voiced
their preference for patients receiving infusions within the organization for the following
reasons. They have better access to patient records and can easily see if infusions were cancelled
or missed. They can also change or update orders within the system resulting in less clerical
support in communicating with outside facilities. Many patients also express a desire to keep all
appointments within one organization. However, the initial workflow revealed that for most
patients, the second and third PA process was necessary when attempting to gain authorization at
a single infusion site. This pattern of repeating PAs led to delays in scheduling for many patients,
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because most insurance companies provide their responses to each request for authorization
seven to thirty days from the date of PA initiation.
Intervention
The first step in the LSS methodology is Defining the problem and desired goal. The
endocrinology team identified the problem. However, there is a lack of understanding the cause
of the problem. This QI project begins by assessing the involvement of the various stakeholders
involved with the Tepezza program. The initial workflow was mapped on a flow chart following
the first meeting held with all stakeholders (see Appendix I). Departments represented included
the endocrine clinic, the central pharmacy, the ambulatory infusion center, the home infusion
unit, the patient financial clearance team, and the pharmaceutical company.
The next step in LSS is Measuring data. The team ran a report to identify all current
patients who were ordered Tepezza within the past twelve months. As mentioned, thirty-six
patients were identified and twelve were waiting to be scheduled. The third step is Analyzing the
data. Together the team narrowed down the suspected causes of the delay in treatment; prior
authorizations are not processed timely, and the involved departments do not communicate with
one another during that process. During the Improvement phase, which is the fourth step in the
DMAIC process, the team created a new flow chart with an updated plan aimed at reducing
delays in Tepezza. The Improvement phase also included scheduling regular meetings with all
stakeholders. The last step in the DMAIC cycle is the Control phase. It is in this step that the
team tracks the progress of the interventions (Monday, 2022). The team repeated the steps of
DMAIC or the Plan-Do-Study-Act (PDSA) cycle twice during this project, and new flow charts
were created to reflect the updated workflows (see Appendix I).
Study of the Intervention
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There were two initial interventions for this project. The first was to keep track of current
patients who are prescribed Tepezza on an Excel spreadsheet for the purpose of measuring the
length of time from order to first infusion. This data collection began during the Measure phase
of the DMAIC model. Patients were tracked on a spreadsheet shared securely between staff who
were identified as team leads for the Tepezza program and the ordering providers. The data
collection not only allowed for the measuring of days from order to initial infusion, but it also
allowed for up-to-date communication with the ordering providers regarding status of prior
authorization and the initiation of therapy. This communication was found to have an added
benefit of helping providers know when a patient should be scheduled for follow up. This
knowledge has led to a decrease in unproductive and costly office visits, which were occurring
prior to the launch of this project.
The second intervention was to conduct regular meetings with stakeholders for the
purpose of improving communication. The clinic QI team had previously been identified. During
the Define stage of DMAIC, this team analyzed and identified the other involved stakeholders in
the Tepezza program. The various stakeholders, including ordering physicians, clinic staff,
infusion center staff, the patient financial clearance team, colleagues from the central pharmacy,
and the pharmaceutical representatives, were interviewed separately at the beginning of the
project to assess their understanding of the Tepezza program, their current workflows, and what
they believe is contributing to the delay in treatment. The various departments were not in
regular contact with one another at that time. Of those interviewed, no one had a specific contact
or point person(s) within the other departments to reach out to for communicating updates or
other information. These meetings began during the Act phase of the DMAIC cycle.
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A third intervention was identified later by the QI team, included educating patients who
have been prescribed Tepezza and educating the endocrinology team on the new workflow and
process. One way this intervention was accomplished was to create a patient pamphlet outlining
the expected timeline for authorization and scheduling, the possible infusion locations, and
important phone numbers and resources during this process (see Appendix J). The patient
pamphlet was presented and put into use by clinic staff during the Improve stage of DMAIC.
Providing patient education and setting expectations has helped to create a better
partnership between the healthcare team and the patient. This has improved patient safety,
outcomes, and satisfaction. Another instructional intervention was aimed at staff education. Each
ordering provider has a support team including a registered nurse and a medical assistant. One
person from each discipline was identified as an ongoing lead for the Tepezza program.
Education for the staff and the plan for maintaining the new workflow was presented to the team
during the Control phase of DMAIC.
Improvements were tested and reassessed using the Plan-Do-Study-Act (PDSA)
measurement strategy (see Appendix K). During the Plan phase of the team’s first PDSA cycle,
the clinic QI team predicted that the delays in the initial Tepezza infusions were caused by an
ineffective PA process and a lack of communication. The original twelve patients awaiting PA
approval had so far waited for an average of 61 days (see Appendix L). The clinic QI team
invited the Patient Financial Clearance (PFC) team to a meeting to discuss current lengths of
time to process Tepezza PAs. They also predicted that an initial positive change would take at
least 30 days to measure.
During the Do phase of the initial PDSA cycle, the QI team met with the PFC team. They
learned that when a Tepezza order is placed, it falls into the PFC work queue instantly. PA
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approval averages three to fourteen days for urgent orders and seven to thirty days for non-urgent
orders. The team also learned that the organization’s outpatient infusion center is notified of
approved and denied PAs in a timely manner, as once processed, this information presents in a
work queue shared between the PFC and infusion center teams (personal communication, 2021).
During the meeting, the team learned that the delay is not due to an untimely or ineffective PA
process. However, the ordering provider and the clinic team are not receiving communication
about approvals or denials.
In the Study phase, the QI team learned that one of the initial predictions was true, the
lack of communication is one reason for the delay in treatment. Yet, the second prediction, which
was an untimely PA process, was disproven. They moved on to the Act phase of the PDSA
cycle. During this cycle, the QI team reevaluated their initial prediction by repeating the PDSA
cycle to identify other possible causes of the delay in treatment. It was also in this phase that the
team sent calendar invitations to identified members from the involved departments. These
meetings have been held consistently since that time. During other PDSA cycles, it was
discovered that the main reason for the delay in scheduling initial Tepezza infusions was that
there were multiple PA cycles for some patients. With this discovery, workflows were changed
to include the performance of a benefits investigation by the Tepezza representatives at the time
of order placement. The benefits investigation provides quick information regarding approved
infusions sites for each patient’s insurance plan. With this knowledge, patients are now being
immediately referred to approved locations, eliminating the need for multiple PAs.
Measures
A family of measures were used to assess the project goal of reducing the number of days
from Tepezza order to infusion, including outcome measures, process measures, and balancing
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measures. For outcome measure, the QI team focused on the number of days between each new
Tepezza order until the day of the first infusion. A second outcome measure considered was the
improvement in communication amongst the involved departments. The last outcome measure
studied was the effectiveness of the patient and staff education tools introduced to the endocrine
staff and patients. The team also recognized the opportunity to provide training to the other staff
members.
Process measures included following each new Tepezza order and tracking the process on
an excel spreadsheet, securely shared between team leads and ordering physicians. Process
measures for the goal of improved communication among stakeholders includes the continuation
of regularly scheduled meetings among the involved departments. Another process measure
focused on the goal of providing effective education and setting appropriate expectations for the
patient include assessing each patient’s understanding of information given to them about the PA
and scheduling process for the ordered Tepezza therapy. Another process measure included
assessing patient satisfaction scores about their experience, and adjusting the workflows as
needed in considering patient feedback. Balancing measures would focus on minimizing delays
in treatment, which will decrease unproductive office visits and hospitalizations. Another
balancing measure is assuring that new workflows do not place any unintended burden on the
other stakeholders involved.
Ethical Considerations
This project is in line with Jesuit values and the American Nurses Association ethical
standards which teach autonomy, beneficence, justice, and non-maleficence. Beneficence
charges all healthcare workers to practice under the moral obligation of doing what is right for
our patients, colleagues, and society. Justice in healthcare implies that care should be fair and
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equitable. And non-maleficence means that healthcare workers practice with the intention of
doing no harm. This project was initiated out of the urgency of concerned healthcare workers
within the microsystem of an endocrinology clinic. The staff and provider concern and the drive
to improve the process for TED patients is in line with the Jesuit value of cura personalis, or care
for the whole person (University of San Francisco, 2022). It is also in line with the ANA Code of
Ethics (COE). Though this project relates to several areas of the COE, provisions 3 and 8 are
most remarkable (ANA, 2015).
The ANA COE provision 3.4 discusses the nurses’ responsibility to promote a culture of
safety, including taking part in identifying a need for and developing new policies that assure
safe practice. In addition, provision 8.3 considers that nurses must be leaders in working with
other healthcare professionals to assure equity and human rights to healthcare are maintained
(ANA, 2015).
This project meets the criteria for an evidence-based change in practice project (see
Appendix M). It does not include the requirements of a human research project per the guidelines
set by the Institutional Review Board (IRB). This project has been implemented as a clinic wide
improvement project and subsequently a clinic protocol will be initiated and maintained.
Section IV: Results
Outcome Measure Results
Though the original team prediction regarding the reason for delays in treatment were not
accurate, with repeated PDSA cycle assessment, the team identified the reason for the gap in
care. The delay was found to be a direct result of the initial attempt to schedule infusions to be
administered at one location, the internal infusion center. This caused a delay for all patients not
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authorized for medication administration within the organization. For patients not authorized for
in-house facilities, a second, and sometimes third, authorization was required.
The project met the goal of decreasing the number of days from when a new Tepezza
order is placed and when patients receive their first infusion. Since improving the workflows,
96% of patients with new Tepezza orders are scheduled for their first Tepezza infusion within 30
days of the order being placed. The project also met the secondary goals of improving
communication between stakeholders, as evidenced by continued weekly meetings. In addition,
improved patient education has had a favorable impact the patient experience. Though
satisfaction rates specific to the Tepezza program were not measured before the project, during
the project the QI team established a simple patient survey to solicit information regarding
patient satisfaction and feedback (see Appendix N). This survey is currently being implemented
in the clinic practice.
Section V: Discussion
Summary
In summary, the improvement project has been successful. The team met their stated goal
of decreasing the days from order to infusion from 61 days to 30 days or less in 96% of patients
with new Tepezza orders. The key finding is that there was an organizational interest, and
sometimes patient preference, in maintaining the scheduling of infusions within the organization,
rather than referring patients to payer preferred external infusion centers. This finding is not in
line with the ANA COE or Jesuit values, and harm was being done to patients because of this
practice. The change in practice has been successful because the involved departments,
prescribing providers and the pharmaceutical manufacturer, worked together to align their goals.
One lesson learned is that it is not always in the patient’s best interest to try to obtain
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authorization in a specific location. Another lesson and previously missed opportunity is this; it
is the responsibility of the healthcare team to educate patients on the insurance authorization
process, any potential delay, and the possible consequences of those delays.
Conclusion
In conclusion, the endocrinology team has been successful in improving the delay in care
from the time a Tepezza order is placed to the time the first dose is administered. The team was
actively engaged in the improvement process and in the Lean Six Sigma methodology of Define,
Measure, Analyze, Improve and Control. The sustainability plan includes maintaining the clinic
team leads, who will continue to follow trends and collect data measuring days from order to
infusion of Tepezza for the TED patients in the endocrinology clinic. In addition, the
departments involved in the Tepezza program will maintain active communication by continuing
regularly scheduled meetings. Patients will continue to receive educational materials and
satisfaction surveys.
The practice has been positively impacted, as most patients are now receiving their
needed therapy in a timely manner. In addition, this project has eliminated wasted office visit
slots, which are costly to patients and unproductive for the provider-patient relationship. Though
this project considered only one intravenous medication, it is possible that other areas within the
organization are facing similar delays in care with ordered therapies. This project was initiated at
the microsystem level. However, it is possible that the success of this project could expand to the
organization’s macrosystem in the future.
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Pie graph

29
Appendix C
Evidence Tables
Evidence Citation
Chin et al. (2020)

Evidence Citation
Smith et al., (2017)

Design
Quasi-experimental,
retrospective

Design
Double-masked,
randomized, placebocontrolled trial

Sample
Researchers studied fifty-seven articles,
including 26,804 patients (n=26,804) to
assess the global prevalence of thyroid
eye disease (TED) in patients a known
diagnosis of Graves’ disease (GD).
They also studied the prevalence of the
most common presenting symptoms.

Sample
A total of 88 TED patients (n=88) aged
17 to 75 years old were selected at
random to either receive Tepezza
(teprotumumab) or a placebo by IV
infusion every three weeks for 24
weeks.

Findings
Of the articles studied, the overall global
prevalence of TED in patients with
known (GD) was 40% and by continent
or region was 38% for Europe, 44% for
Asia, 27% for North America, 58% for
Oceania, 35% in Southeast Asia, and
48% in the Middle East. The most
common presenting symptoms in TED
patients were lid retraction and
proptosis, found in 57%, diplopia in
36%, and ocular hypertension in 13%.
Regular screening for TED in patients
with GD could reduce worsening
symptoms and improve outcomes.

JHNEBP Appraisal Rating
JHNEBP Critical Appraisal Tool and
Rating: JHNEBP Level II B

Findings
A total of 76 patients completed the
study. Tepezza was found to be more
effective than the placebo. At week 6,
43% of patients who received Tepezza
showed improvement versus 4% in the
placebo group. And at week 24, 69% of
patients who received Tepezza showed
improvement versus 20% in the placebo
group.

JHNEBP Appraisal Rating
JHNEBP Critical Appraisal Tool and
Rating: JHNEBP Level I B

Strengths: There was a large number of
GD patients identified. Researchers
considered articles since the
establishment of TED as a diagnosis.
Limitations: There was a lack of
standardized classification of TED
worldwide, which could be considered a
bias. Also, there were few articles from
Africa and Oceania.

Strengths: This study was done over
26 months at 15 locations.

Limitations: The study did not
consider patients with mild or less active
TED. This study does not evaluate on
ongoing response to treatment with
Tepezza for longer than one year.
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Evidence Citation
Wallace et al., (2020)

Evidence Citation
Douglas, (2019)

Design
Sample
Retrospective cohort This study reviewed records of 225
patients (n=225) who required a prior
authorization (PA) for a prescribed
infusion treatment.

Design
Randomized control
trial

Sample
This study included 112 patients
(n=112) who were 18 to 75 years old.
The patients studied had been diagnosed
with active TED for less than 9 months
and had no prior treatment.

Findings
Of the 225 patients, 71% required a PA,
and 21% of these PAs were initially
denied. The denials went through the
additional process of appeal and peer-topeer meetings. These processes lead to
delays in care and poorer outcomes for
patients. Because most PAs are
approved, PA requirements should be
reconsidered.

JHNEBP Appraisal Rating

Findings
Tepezza could offer an alternative to
surgery, as its effects were comparable
to the effect after nerve decompression
surgery.

JHNEBP Appraisal Rating
JHNEBP Critical Appraisal Tool and
Rating: JHNEBP Level I A

JHNEBP Critical Appraisal Tool and
Rating: JHNEBP Level III A
Strengths: The study considered the
effects current PA requirements have on
both patients and providers.

Limitations: This study was conducted
at only one location and included
required PAs for IV infusions only.

Strengths: 76 patients completed the
full course of treatment. Baseline data
for the placebo and the Tepezza groups
were similar.
Limitations: This study represents
phase II. Further studies are needed to
come to desired conclusion.
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Evidence Citation
Munoz-Ortiz, et al.,
(2020)

Design
Retrospective cohort
and cross-sectional
study

Sample
This study included the review of
thirteen articles from four continents
which met the inclusion criteria of
patients having a TED diagnosis, record
of thyroid function labs, and a diagnosis
of a primary thyroid condition.

Findings
TED can be present in patients with
normal thyroid function tests.
Researchers encourage providers to
obtain additional testing if patients
present with symptoms of TED.

JHNEBP Appraisal Rating
JHNEBP Critical Appraisal Tool and
Rating: JHNEBP Level III B
Strengths: The study was performed
with data from four continents.
Limitations: There is no (n) for this
study. Every continent was not included.
Researchers recognize a lack of data
from Latin American countries.

32
Appendix D
Project Charter
Title:
Improving the workflow for new Tepezza orders
Global aim:
This quality improvement project is aimed at improving the gap in time from when Tepezza is
ordered until the first infusion is administered. Tepezza is prescribed to treat severe thyroid eye
disease. A delay in care could mean further loss of vision and even total loss of vision.
Improving the gap in time will decrease the chances of vision loss and worsening symptoms for
patients.
Specific aim:
How does improved communication between all stakeholders who are involved with the
ordering, authorization, and scheduling of Tepezza administration decrease the length of time
between when the medication is ordered to the first infusion, within six months, as compared to
the current workflow which includes a lack of communication between involved departments
and patients?
Background information/rationale for project:
Thyroid Eye Disease (TED) is the most common autoimmune disease affecting the eye (MunozOrtiz et al., 2020). It is diagnosed most often in patients who have Graves’ disease. Thyroid Eye
Disease is progressive, with the active phase lasting from six to 24 months (National
Organization for Rare Disorders [NORD], 2021). Thyroid eye disease is usually diagnosed when
the optic nerve is compressed, leading to various changes in vision including loss of color vision,
loss of sharpness of vision, and dimmed vision. Other reported symptoms of TED include
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blurred vision, diplopia, eye pain, photophobia, tearing of the eye, restricted eye movement,
retraction of the eyelids, and exophthalmos. In severe cases of TED, patients could develop
corneal ulcers and permanent loss of vision (Cleveland Clinic, 2021).
Tepezza (teprotumumab) is a medication prescribed to treat severe thyroid eye disease
(TED). In the microsystem of an ambulatory endocrinology clinic, there is a gap in care from
when Tepezza is ordered and when patients are scheduled for their initial infusion. Sometimes,
this gap in time proves detrimental to patients’ health. An unnecessary delay in scheduling this
infusion could result in a decrease in quality of life, worsening symptoms, and blindness.
There are two main causes identified by the ordering providers for the delay in initiating
the prescribed treatment. These include delays in insurance authorization and lack of
communication between departments. Currently, patients are waiting more than 60 days before
being scheduled for their prescribed treatments if they are scheduled at all.
Sponsors:
Clinic Manager

Name redacted

Endocrinologist

Name redacted

Ophthalmologist

Name redacted

Goals for the Project:
The goal is to decrease the time from when a new Tepezza order is placed and when a patient is
scheduled for their first infusion by increasing communication among stakeholders and patients.
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Measures; outcome, process, balancing:

Measure

Data Source

Target

Chart review, meetings
with team

90%

Outcome

Schedule all patients prescribed
Tepezza within 30 days of order
Process

Track each patient who is intended to
Chart review
receive Tepezza through the time of the
first infusion

90%

Continue regular meetings with various
stakeholders

Team meetings

90%

Chart review

Less than 10%

Balancing

Minimize delays in the initiation of
treatment

QI Team members:
Clinic Manager

Name redacted

Clinic RN

Name redacted

Clinic MA

Name redacted

Endocrinologist

Name redacted

Ophthalmologist

Name redacted
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Appendix E
Budget
Tepezza: Improving Delays in Treatment: Business Plan
Problem
Thyroid eye disease is a progressive disease, commonly diagnosed when the optic nerve
is compressed leading to various changes in vision and vision loss (National Organization for
Rare Disorders [NORD], 2021). Though other treatments exist for symptom relief, Tepezza is
the only FDA approved treatment for TED (Horizon Therapeutics, 2022). There is a delay in
care from when a Tepezza order is placed and when a patient receives their first infusion. This
gap in care contributes to patient harm and a decrease in quality of life. In 2017 there were an
identified 3,493 emergency department visits related to thyroid eye disease (TED), with each
visit incurring an average cost of $6,018. In that same year, there were a recoded 1,870
hospitalizations for TED patients, incurring an average cost of $59,103 per admission (Singh et
al., 2021).
Prior authorization (PA) is a lengthy process and is required by insurance companies for
most infused medications (Wallace et al., 2019). In addition, within the organization, there is a
lack of communication amongst stakeholders involved in the Tepezza program about PA
authorizations and denials. This contributes to a lack of coordination of care which furthers the
delay in treatment.
Quality Improvement
A clinical quality improvement (QI) team was identified. This team collected data
regarding the following; the number of days from the time a new Tepezza order is placed and a
patient’s initial infusion, average staff hours for each discipline required for the ongoing
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maintenance of the project, the number of unproductive office visits related to the lack of
communication amongst stakeholders. The Lean Six Sigma methodology of define, measure,
analyze, improve, and control (DMAIC) was chosen as a guide for this project. Within this
methodology, the QI team performed the Plan-Do-Study-Act (DSA) cycle as needed for the
project (Monday, 2022).
Proposed Solution
The proposed solution is adding staffing hours needed for the ongoing success of the
Tepezza program to the existing annual operational budget. There is also the one-time cost of
providing a staff education training. Aside from the labor and staff training costs associated with
this project, there are no capital or non-capital purchases needed. Providing patients with the
additional staff support will decrease hospitalizations and unproductive office visits.
Annual Budget
Within the organization where the QI project occurred, the average hourly wage for a
clinical nurse is $82.00 and for a medical assistant is $36.00 (Indeed.com, 2022). Though the QI
team meets more frequently during the current project, the proposal requested is to add the
ongoing labor costs to the annual operating budget. It is estimated that ongoing labor costs will
include 78 additional staffing hours per year for one registered nurse (RN) and 78 additional
staffing hours for one medical assistant (MA). Annually this incurs the additional costs of
$6,400.00 for RN support and $2,800.00 for MA support.
The clinic staff includes three advanced practice providers (APP), five RNs, and fourteen
MAs. The one-time staff training session is expected to last for one hour. The APP team are
salaried staff and were not included in the estimated budget for training. For the RN and MA
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teams, it is estimated that a one hour training session will incur additional labor costs of
approximately $900.00.
In the clinic assessed, approximately four patients receive a new order for Tepezza every
month. It is estimated that a return patient office visit in the clinic incurs fees of up to $712.00
per visit. This is a waste of resources and could cause an unnecessary expense for the patients
who return to see the ordering provider before beginning their Tepezza treatment.
This investment in labor costs will generate a return on investment (ROI) qualifying as a
quality improvement project. The ROI is calculated by considering the prevention of costs
associated with unproductive clinic visits. It’s estimated that prior to implementation of the QI
project, only 25% of patients prescribed Tepezza received their first infusion within 30 days of
the order placement. At least 50% of the remaining patients prevented to clinic for unproductive
office visits that were scheduled as a follow up to the initiation of treatment with Tepezza. For
budget purposes, the ROI was calculated based on the average of 36 patients per year who are
prescribed Tepezza. Based on previous calculations, nine patients or 25%, would be scheduled
within 30 days prior to the QI project. Of the remaining 25 patients, an estimated 14 patients will
have unproductive clinic visits. Based on the current cost of a return visit to clinic of $712.00,
the annual cost of wasted visits totals approximately $10,000.00 ($712.00 X 14 patients per
year).
The first year budget is estimated at $10,100.00 and includes additional labor and staff
training. The budget for additional years in $9300.00 annually. This project is considered a
break-even analysis. The ROI does not consider the additional intangible benefits gained by
decreasing hospitalizations and decreased labor in other departments associated with the QI
project.
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Appendix F
Microsystem Assessment
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Appendix G
IHI Clinical Microsystem Assessment Tool
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Appendix H
SWOT analysis
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Appendix I
The Three Stages of Flow Charts Used During the Project
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Appendix J
Patient Education Pamphlet
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Appendix K
Plan Do Study Act (PDSA) Cycle
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Pre- and Post-Project Data
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Statement of Non-Research Determination Form
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Appendix N
Patient Satisfaction Survey

